An ASX blue-chip healthcare share to buy and hold forever

The ASX healthcare sector has provided stellar returns to investors over the past decade and there continues to be a range of high-quality companies worth considering for your portfolio. Here is why I think CSL Limited (ASX: CSL) is one of them.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ASX healthcare sector has provided stellar returns to investors over the past decade and there continues to be a range of high-quality companies worth considering for your portfolio.  I believe this ASX blue-chip healthcare share is worth considering:

CSL Limited (ASX: CSL)

CSL Limited is a global biotechnology manufacturer that researches, develops, and markets products to treat and prevent rare and serious diseases.

CSL has a broad range of products in its portfolio that generate revenue across different therapeutic groups.  There is good diversification in earnings through the different groups, which include: Immunoglobulins, Haemophilia, Albumin, and specialty products.

Along with this, CSL consistently has a pipeline of research and development projects to promote further growth down the track.  In its half-yearly results presentation, CSL alluded to five new products moving into the human trial phase which demonstrates the company's innovation.

The CSL share price has come down significantly off its 52-week high of $232 after slightly softer than expected results.  It currently has a P/E ratio of 32.5 which may look expensive, but this is due to investors continuing to expect a fast growth rate in earnings, which currently sits at a healthy $5 per share.

Total revenue was up 11% from the corresponding period in FY18 and NPAT grew by 10%.  Return on invested capital was slightly down at 29.9%.

The outlook for FY2019 indicates that CSL expects strong demand for its therapies to continue.  Seqirus demand is expected to be lower in this upcoming half due to seasonality, as the northern hemisphere has greater demand for this flu treatment and that part of the world is heading into warmer seasons.  Along with this, CSL expects FY2019 NPAT to be at the top end of the guidance range.

Foolish Takeaway

Investors can easily be caught up in trying to pick beaten down shares in low-quality companies, hoping for an inspirational comeback story.  CSL Limited is a star quality company which has shown time after time that it can create new products, launch them successfully, increase earnings and repeat the process.

I think the CSL share price will continue to succeed long into the future and would be comfortable to buy and hold at any time.  This recent announcement seems to have opened a window of opportunity for investors to buy in.

If you don't think CSL Limited is the healthcare company for you, I would consider researching Cochlear Limited (ASX: COH).

Motley Fool contributor Michael Guinery owns shares in CSL Limited. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Investor sitting in front of multiple screens watching share prices
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave the thumbs up to these ASX shares last week. Why are they bullish?

Read more »

Jessica Amir
Investing Strategies

6 ASX shares to buy and hold until the next leap year

These are the stocks to store in the portfolio until the next February 29 rolls around in 2028, according to…

Read more »

A woman ponders a question as she puts money into a piggy bank with a model plane and suitcase nearby.
Share Market News

If I invest $10,000 in Qantas shares, how much passive income will I receive in 2024?

Here's what analysts are predicting from the airline operator.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

These ASX 200 shares could rise 20% to 50%

Big returns could be on the cards according to analysts.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Value Investing

Looking for ASX value shares? Here's 1 I'd buy and 1 I'd avoid!

It's not an easy exercise to identify which stocks are undervalued and which ones are simply terrible. Here's an example…

Read more »

A young girl looks up and balances a pencil on her nose, while thinking about a decision she has to make.

Will I be buying Zip shares now the company has turned a profit?

Is now the right time to buy this BNPL stock -- or not?

Read more »

a man with hands in pockets and a serious look on his face stares out of an office window onto a landscape of highrise office buildings in an urban landscape

1 ASX dividend stock down 55% to buy right now

Here's why I think this beaten-up stock could be an opportunity.

Read more »

Three analysts look at tech options on a wall screen
Share Market News

Here's how the ASX 200 market sectors stacked up this week

ASX tech shares are on fire, leading the 11 market sectors for a third consecutive week.

Read more »